Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Commercial genetic profiling services should provide detailed information about test results: Report

Direct-to-consumer personal genetic profiling services that claim to predict people's health risks by analysing their DNA are often inconclusive and companies that sell them should provide better information about the evidence on which the results are based, says the UK Nuffield Council on Bioethics, in a new report on the ethics of so-called personalised healthcare services.

13 Oct 2010

Adeona announces five scientific publications on Alzheimer's disease and cognitive decline

Adeona Pharmaceuticals, Inc., announced five scientific publications on the role of copper toxicity and zinc deficiency in Alzheimer's disease and cognitive decline.

12 Oct 2010

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

H. Lundbeck A/S (Lundbeck) and Merck, known outside the United States and Canada as MSD, today announced a commercialization agreement for SYCREST (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST in all markets outside the United States, China and Japan. Lundbeck expects to launch SYCREST in the European Union (EU), where it is already approved, at the beginning of 2011.

12 Oct 2010

Synosia announces $30M Series C financing

Synosia Therapeutics, a privately held biotherapeutics company focused on neurology and psychiatry, today announced that it has raised $30M in a Series C financing round.

12 Oct 2010

UCB, Synosia Therapeutics announce new strategic partnership in neurology

UCB and Synosia Therapeutics announced today a new strategic partnership in neurology. Synosia has granted UCB a license for exclusive, worldwide rights to the development compound SYN-115 and rights to a second compound, SYN-118, for non-orphan indications. Both are in Phase II clinical development for the treatment of Parkinson's disease.

12 Oct 2010

New microchip technology to identify neuronal regenerators

Scientists have long sought the ability to regenerate nerve cells, or neurons, which could offer a new way to treat spinal-cord damage as well as neurological diseases such as Alzheimer's or Parkinson's. Many chemicals can regenerate neurons grown in Petri dishes in the lab, but it's difficult and time-consuming to identify those chemicals that work in live animals, which is critical for developing drugs for humans.

12 Oct 2010

Embryonic stem cells used in first trial for spinal cord injury

The first ever patient to receive treatment in a U.S. government approved study involving human embryonic stem cells has been injected with millions of the potentially life saving cells. He is presently being treated at the Shepherd Center in Atlanta. He was partially paralyzed following a spinal cord injury. The center specializes in treating these types of injuries.

11 Oct 2010

MOH approves BrainStorm's NurOwn stem cell therapy for Phase I/II clinical trial

BrainStorm Cell Therapeutics Inc. a leading developer of adult stem cell technologies and therapeutics, today announced that the Israeli Ministry of Health (MOH) has granted clearance for a Phase I/II clinical trial using the company's autologous NurOwn stem cell therapy in patients with amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's Disease.

11 Oct 2010

ESC pleased with European Health Award recognition for Chronic Disease Alliance

The European Society of Cardiology is delighted to see the European Health Award 2010 handed to the Chronic Disease Alliance at the 13th European Health Forum held in Gastein 6 - 9 October 2010.

11 Oct 2010

Cell Cure to receive equity investment of $7.1 million to develop stem cell-based therapies

BioTime, Inc. Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure will receive an equity investment of $7.1 million from BioTime, Teva Pharmaceutical Industries Ltd., and Hadasit Bio-Holdings (HBL).

11 Oct 2010

Study finds boosting mitochondria may delay onset of Parkinson's disease

In a study that sheds new light on the causes of Parkinson's disease, researchers report that brain cells in Parkinson's patients abandon their energy-producing machinery, the mitochondria. A shutdown in fuel can have devastating effects on brain cells, which consume roughly 20 percent of the body's energy despite making up only 2 percent of body weight.

8 Oct 2010

Scientists engineer bacterial cell wall with small molecules to combat diseases

A team of Yale University scientists has engineered the cell wall of the Staphylococcus aureus bacteria, tricking it into incorporating foreign small molecules and embedding them within the cell wall.

8 Oct 2010

Parkinson’s disease pathology breakthrough

Researchers have found that brain cells of people with early Parkinson's disease have damaged powerhouses. In a new study they have identified 10 groups of gene sets related to the energy production problems in the brain cells of these people.

8 Oct 2010

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

Cortex Pharmaceuticals, Inc. announced that the rights to a published patent application entitled, "Pharmacological Modulation of Positive AMPA Receptor Modulator Effects on Neurotrophin Expression", has been licensed exclusively to Cortex from the University of California.

7 Oct 2010

Congress scientific program to highlight new developments in Parkinson's disease

The 7th International Congress on Mental Dysfunction & Other Non-Motor Features in Parkinson's Disease (MDPD 2010), to be held in Barcelona, December 9 - 12, 2010, aims to provide specialists with the latest developments in the understanding of cognitive and psychiatric aspects of the disease.

7 Oct 2010

Michael J. Fox Foundation for Parkinson's Research announces awards totaling $10.1M

The Michael J. Fox Foundation for Parkinson's Research announced awards totaling approximately $10.1 million for five new clinical studies and 14 pre-clinical therapeutic development projects. The funding includes $2.5 million to drive four new clinical trials under the Clinical Intervention Awards, one of the Foundation's Edmond J. Safra Core Programs for PD Research.

6 Oct 2010

NeuroDerm receives $1M grant for development of ND0611 dermal patch for Parkinson's disease

NeuroDerm, Ltd. was informed today that it was awarded a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research. These funds will support the next clinical study with ND0611, a new dermal patch for the treatment of Parkinson's disease, as part of the Foundation's prestigious Clinical Intervention Awards 2010 program. This study will evaluate the safety, tolerability, levodopa pharmacokinetics, and possible clinical benefits of ND0611 in advanced Parkinson's disease patients.

6 Oct 2010

FDA clears Integra LifeSciences' Vu aPOD Prime anterior lumbar interbody fusion device

Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.

6 Oct 2010

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

The Focused Ultrasound Surgery Foundation is hosting the 2nd International Symposium on MR-guided Focused Ultrasound in Chantilly, Virginia from October 17-20. Leading researchers and clinicians from around the world will gather at the three-day scientific conference to present and discuss the latest advancements in one of the most revolutionary and promising areas of therapeutic medicine.

6 Oct 2010

Diamond-coated electrodes for implantable devices

Diamonds adorning tiaras to anklets are treasures but these gemstones inside the body may prove priceless.

6 Oct 2010

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Commercial genetic profiling services should provide detailed information about test results: Report

Adeona announces five scientific publications on Alzheimer's disease and cognitive decline

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

Synosia announces $30M Series C financing

UCB, Synosia Therapeutics announce new strategic partnership in neurology

New microchip technology to identify neuronal regenerators

Embryonic stem cells used in first trial for spinal cord injury

MOH approves BrainStorm's NurOwn stem cell therapy for Phase I/II clinical trial

ESC pleased with European Health Award recognition for Chronic Disease Alliance

Cell Cure to receive equity investment of $7.1 million to develop stem cell-based therapies

Study finds boosting mitochondria may delay onset of Parkinson's disease

Scientists engineer bacterial cell wall with small molecules to combat diseases

Parkinson’s disease pathology breakthrough

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

Congress scientific program to highlight new developments in Parkinson's disease

Michael J. Fox Foundation for Parkinson's Research announces awards totaling $10.1M

NeuroDerm receives $1M grant for development of ND0611 dermal patch for Parkinson's disease

FDA clears Integra LifeSciences' Vu aPOD Prime anterior lumbar interbody fusion device

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

Diamond-coated electrodes for implantable devices

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in